Summary
This trial will study tisotumab vedotin to find out whether it is an effective treatment
for certain solid tumors and what side effects (unwanted effects) may occur. There are
seven parts to this study.
- In Part A, the treatment will be given to participants every 3 weeks (3-week
cycles).
- In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every
4-week cycle.
- In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every
4-week cycle.
- In Part D, participants will be given treatment on Day 1 of every 3-week cycle.
Participants in Part D will get tisotumab vedotin with either:
- Pembrolizumab or,
- Pembrolizumab and carboplatin, or
- Pembrolizumab and cisplatin
- In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every
4-week cycle.
- In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of
every 6-week cycle. Participants in Part F will get tisotumab vedotin with
pembrolizumab.
- In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of
every 6-week cycle. Participants in Part G will get tisotumab vedotin with
pembrolizumab and carboplatin.